Article Data

  • Views 712
  • Dowloads 128

Original Research

Open Access

Wedelolactone attenuates angiotensin II-stimulated hypertrophy in H9C2 cardiomyocytes

  • Rufeng Zhang1
  • Linlin Jiang2,*,
  • Du Xiong1
  • Chang Bian3
  • Jingjing He1

1Department of Cardiovascular Medicine, Quzhou Hospital of Zhejiang Medical and Health Group, 324004 Quzhou, Zhejiang, China

2Hemodialysis Room, Quzhou Hospital of Zhejiang Medical and Health Group, 324004 Quzhou, Zhejiang, China

3Department of Cardiovascular Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, 310058 Hangzhou, Zhejiang, China

DOI: 10.22514/sv.2024.044 Vol.20,Issue 4,April 2024 pp.75-82

Submitted: 09 January 2024 Accepted: 05 March 2024

Published: 08 April 2024

*Corresponding Author(s): Linlin Jiang E-mail:


Cardiomyocyte hypertrophy is the adaptive response of the heart to various physiological or pathological stresses. To combat this type of disease, more effective drugs are still needed. Wedelolactone is the main ingredient extracted from the medicinal plant Daylily and have effects such as immunomodulatory, anti-fibrosis, and anti-inflammation. However, the role and mechanism of Wedelolactone in myocardial hypertrophy are still unclear. Here, H9C2 cells were treated with Ang II to construct a cardiomyocyte hypertrophy cell model. We found Wedelolactone suppressed the survival of Ang II-induced cardiomyocytes. Wedelolactone further restrained the progression of Ang II-induced cardiomyocyte hypertrophy. Wedelolactone suppressed the oxidative stress of Ang II-induced cardiomyocytes, and restrained the apoptosis. Mechanically, Wedelolactone restrained the progression of Ang II-induced cardiomyocyte hypertrophy via Nuclear factor erythroid 2-related factor 2/Heme oxygenase-1 pathway (Nrf2/HO-1 pathway). In summary, Wedelolactone attenuates angiotensin II-induced hypertrophy and apoptosis in cardiomyocytes. Wedelolactone attenuates angiotensin II-stimulated hypertrophy and apoptosis in cardiomyocytes.


Cardiomyocyte hypertrophy; Wedelolactone; Oxidative stress; Apoptosis; Nrf2/HO-1

Cite and Share

Rufeng Zhang,Linlin Jiang,Du Xiong,Chang Bian,Jingjing He. Wedelolactone attenuates angiotensin II-stimulated hypertrophy in H9C2 cardiomyocytes. Signa Vitae. 2024. 20(4);75-82.


[1] Eggertsen TG, Saucerman JJ. Virtual drug screen reveals context-dependent inhibition of cardiomyocyte hypertrophy. British Journal of Pharmacology. 2023; 180: 2721–2735.

[2] Guo Y, Cen XF, Li D, Qiu HL, Chen YJ, Zhang M, et al. Identify Tcea3 as a novel anti-cardiomyocyte hypertrophy gene involved in fatty acid oxidation and oxidative stress. Frontiers in Cardiovascular Medicine. 2023; 10: 1137429.

[3] Luan Y, Guo G, Luan Y, Yang Y, Yuan R. Single-cell transcriptional profiling of hearts during cardiac hypertrophy reveals the role of MAMs in cardiomyocyte subtype switching. Scientific Reports. 2023; 13: 8339.

[4] Sun H, Zhu G, Ling S, Liu J, Xu JW. 4'-O-methylbavachalcone inhibits succinate induced cardiomyocyte hypertrophy via the NFATc4 pathway. Experimental and Therapeutic Medicine. 2023; 25: 172.

[5] Yue L, Sheng S, Yuan M, Lu J, Li T, Shi Y, et al. HypERlnc attenuates angiotensin II-induced cardiomyocyte hypertrophy via promoting SIRT1 SUMOylation-mediated activation of PGC-1a/PPARa pathway in AC16 cells. Cell Biology International. 2023; 47: 1068–1080.

[6] Johnson J, Yang Y, Bian Z, Schena G, Li Y, Zhang X, et al. Systemic hypoxemia induces cardiomyocyte hypertrophy and right ventricular specific induction of proliferation. Circulation Research. 2023; 132: 723–740.

[7] Gao Y, Zhao D, Xie W, Meng T, Xu C, Liu Y, et al. Rap1GAP mediates angiotensin II-induced cardiomyocyte hypertrophy by inhibiting autophagy and increasing oxidative stress. Oxidative Medicine and Cellular Longevity. 2021; 2021: 7848027.

[8] Wu T, Wang H, Xin X, Yang J, Hou Y, Fang M, et al. An MRTF-A-Sp1-PDE5 axis mediates angiotensin-II-induced cardiomyocyte hypertrophy. Frontiers in Cell and Developmental Biology. 2020; 8: 839.

[9] Achari A, Chatterjee S, Dey S, Kundu TK, Jaisankar P. Catecholase-catalyzed synthesis of wedelolactone, a natural coumestan and its analogs. Organic & Biomolecular Chemistry. 2022; 21: 89–92.

[10] Cao J, Ni Y, Ning X, Zhang H. Wedelolactone ameliorates synovial inflammation and cardiac complications in a murine model of collagen-induced arthritis by inhibiting NF-kB/NLRP3 inflammasome activation. Folia Histochemica et Cytobiologica. 2022; 60: 301–310.

[11] Ha NM, Hop NQ, Son NT. Wedelolactone: a molecule of interests. Fitoterapia. 2023; 164: 105355.

[12] Svrlanska A, Ruhland A, Marschall M, Reuter N, Stamminger T. Wedelolactone inhibits human cytomegalovirus replication by targeting distinct steps of the viral replication cycle. Antiviral Research. 2020; 174: 104677.

[13] Cheng M, Lin J, Li C, Zhao W, Yang H, Lv L, et al. Wedelolactone suppresses IL-1β maturation and neutrophil infiltration in aspergillus fumigatus keratitis. International Immunopharmacology. 2019; 73: 17–22.

[14] Sharma S, Trivedi S, Pandey T, Ranjan S, Trivedi M, Pandey R. Wedelolactone mitigates parkinsonism via alleviating oxidative stress and mitochondrial dysfunction through Nrf2/SKN-1. Molecular Neurobiology. 2021; 58: 65–77.

[15] Sun Y, Li Y, Liu C, Xue R, Dong B, Huang H, et al. The role of angiopoietin-like protein 4 in phenylephrine-induced cardiomyocyte hypertrophy. Bioscience Reports. 2019; 39: BSR20171358.

[16] Xu S, Liu X, Liu X, Shi Y, Jin X, Zhang N, et al. Wedelolactone ameliorates pseudomonas aeruginosa-induced inflammation and corneal injury by suppressing caspase-4/5/11/GSDMD-mediated non-canonical pyroptosis. Experimental Eye Research. 2021; 211: 108750.

[17] Peng L, Huang X, Jin X, Jing Z, Yang L, Zhou Y, et al. Wedelolactone, a plant coumarin, prevents vascular smooth muscle cell proliferation and injury-induced neointimal hyperplasia through Akt and AMPK signaling. Experimental Gerontology. 2017; 96: 73–81.

[18] Ali F, Khan BA, Sultana S. Wedelolactone mitigates UVB induced oxidative stress, inflammation and early tumor promotion events in murine skin: plausible role of NFkB pathway. European Journal of Pharmacology. 2016; 786: 253–264.

[19] Ho MY, Wang CY. Role of irisin in myocardial infarction, heart failure, and cardiac hypertrophy. Cells. 2021; 10: 2103.

[20] Yu T, Sun L, Chen C, Wang Z, Liu X, Zhu F, et al. Xin-Ji-Er-Kang alleviates isoproterenol-induced myocardial hypertrophy in mice through the Nrf2/HO-1 signaling pathway. Evidence-Based Complementary and Alternative Medicine. 2022; 2022: 7229080.

[21] Souza DS, Barreto TO, Menezes-Filho JER, Heimfarth L, Rhana P, Rabelo TK, et al. Myocardial hypertrophy is prevented by farnesol through oxidative stress and ERK1/2 signaling pathways. European Journal of Pharmacology. 2020; 887: 173583.

[22] Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. Journal of Molecular and Cellular Cardiology. 2002; 34: 379–388.

[23] Ren S, Wang Y, Zhang Y, Yan P, Xiao D, Zhao Y, et al. Paeoniflorin alleviates AngII-induced cardiac hypertrophy in H9C2 cells by regulating oxidative stress and Nrf2 signaling pathway. Biomedicine & Pharmacotherapy. 2023; 165: 115253.

[24] Fang M, Luo J, Zhu X, Wu Y, Li X. BRD4 silencing protects angiotensin II-induced cardiac hypertrophy by inhibiting TLR4/NF-kB and activating Nrf2-HO-1 pathways. Cardiology Research and Practice. 2022; 2022: 8372707.

[25] Shi X, Zhang B, Chu Z, Han B, Zhang X, Huang P, et al. Wogonin inhibits cardiac hypertrophy by activating Nrf-2-mediated antioxidant responses. Cardiovascular Therapeutics. 2021; 2021: 9995342.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time